LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for 675 million. Under the terms of the agreement, the assets and associated responsibilities relating to Astellas' global portfolio of dermatology products - which include Protopic, treatment for eczema, and other products for the treatment of acne and skin infection - will be transferred to LEO Pharma .
Anacor Pharma is a heavily institutionally owned biotech stock which is being recommended by sellside analysts who apparently have misunderstood the Phase 3 clinical trial results of their drug Crisaborole - a topical ointment for atopic dermatitis a/k/a eczema. Atopic dermatitis is a skin disease characterized by dry itchy rashes.
Anacor is working toward bringing its boron-based topical anti-inflammatory phosphodiesterase 4 inhibitor to the market. However, when diving down into the competitive landscape of therapies for atopic dermatitis in adults and children, one finds a complicated picture.